Enlivex anticipates releasing topline data from the Phase II stage, including full three-month endpoints, by this August.

Future research should include a larger number of patients with knee osteoarthritis. SAN DIEGO — Results presented here showed intra-articular injections of platelet-rich plasma may be inferior ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

Swiss pharma major Novartis has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending ...

Enlivex believes Allocetra™ has the potential to transform osteoarthritis treatment ... and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and ...

The Department of Health - Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in ...

MSK Doctors has released a new report detailing the positive impact that Arthrosamid has had on recent knee osteoarthritis patients, exploring the innovative hydrogel injection treatment in depth.

DelveInsight's “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

With Japan’s rapidly aging population, the prevalence of knee osteoarthritis is expected to rise. This has led to an increased demand for non-surgical treatment options, such as knee hyaluronic acid ...

Osteoarthritis is a common chronic health condition that is characterised by joint pain and restricted movement. The main ...